CurrentRheuma — newest BriefsClinically relevant rheumatology research, summarized, structured and curated.https://currentrheuma.com/feed.xml2026-11-14T17:15:27.870ZCurrentRheumahttps://currentrheuma.com/Real-world avacopan use in ANCA-associated vasculitis: glucocorticoid exposure and healthcare resource utilization from US claims datahttps://currentrheuma.com/studies/real-world-avacopan-use-in-anca-associated-vasculitis-glucocorticoid-exposure-2026/2026-11-14T17:15:27.870Z2026-11-14T17:15:27.870ZCohort study · Rheumatology (Oxford), 2026.Association between cognitive trajectories and subsequent hip fracture risk: a multinational prospective cohort studyhttps://currentrheuma.com/studies/association-between-cognitive-trajectories-and-subsequent-hip-fracture-risk-a-2026/2026-11-13T23:15:27.309Z2026-11-13T23:15:27.309ZCohort study · Osteoporos Int, 2026.Physical and psychosocial morbidity in pregnancy and lactation-associated osteoporosis: a comprehensive mixed-methods studyhttps://currentrheuma.com/studies/physical-and-psychosocial-morbidity-in-pregnancy-and-lactation-associated-2026/2026-11-13T23:15:27.309Z2026-11-13T23:15:27.309ZCase-control study · Osteoporos Int, 2026.Glucocorticoid purchases and methotrexate persistence in early rheumatoid arthritis in Finlandhttps://currentrheuma.com/studies/glucocorticoid-purchases-and-methotrexate-persistence-in-early-rheumatoid-2026/2026-11-13T17:28:41.089Z2026-11-13T17:28:41.089ZResearch article · Scand J Rheumatol, 2026.Development and validation of a text-mining-based algorithm for detection of rare hereditary periodic fever syndromeshttps://currentrheuma.com/studies/development-and-validation-of-a-text-mining-based-algorithm-for-detection-of-2026/2026-11-13T13:15:46.883Z2026-11-13T13:15:46.883ZDiagnostic or prognostic study · Rheumatology (Oxford), 2026.Clinical characteristics, inflammatory biomarkers and genetic background of patients with non-hereditary periodic fever syndromeshttps://currentrheuma.com/studies/clinical-characteristics-inflammatory-biomarkers-and-genetic-background-of-2026/2026-11-13T11:15:45.584Z2026-11-13T11:15:45.584ZCohort study · RMD Open, 2026.Early life infections, antibiotics and later risk of juvenile idiopathic arthritis: evidence from two Scandinavian birth cohorts with exploratory genetic analyseshttps://currentrheuma.com/studies/early-life-infections-antibiotics-later-risk-juvenile-idiopathic-arthritis-2026/2026-11-13T11:15:45.584Z2026-11-13T11:15:45.584ZMeta-analysis · RMD Open, 2026.Measurement of kidney disease in a novel multidomain treatment response measure for SLE clinical trialshttps://currentrheuma.com/studies/measurement-of-kidney-disease-in-a-novel-multidomain-treatment-response-measure-2026/2026-11-13T11:15:45.584Z2026-11-13T11:15:45.584ZGuideline or statement · Lupus Sci Med, 2026.Real-world discontinuation of immunosuppressive therapy after proliferative lupus nephritis: the overlooked impact of non-adherence (MASSILUP-WIN)https://currentrheuma.com/studies/real-world-discontinuation-immunosuppressive-therapy-after-proliferative-lupus-2026/2026-11-13T11:15:45.584Z2026-11-13T11:15:45.584ZCohort study · Lupus Sci Med, 2026.Risk-stratified effectiveness of direct oral anticoagulants versus vitamin K antagonists in thrombotic antiphospholipid syndrome: a prospective cohort studyhttps://currentrheuma.com/studies/risk-stratified-effectiveness-of-direct-oral-anticoagulants-versus-vitamin-k-2026/2026-11-13T11:15:45.584Z2026-11-13T11:15:45.584ZCohort study · Lupus Sci Med, 2026.Janus Kinase inhibitors in refractory Takayasu arteritis: a systematic review and proportion meta-analysis of efficacy and safetyhttps://currentrheuma.com/studies/janus-kinase-inhibitors-in-refractory-takayasu-arteritis-a-systematic-review-and-2026/2026-11-13T09:15:36.833Z2026-11-13T09:15:36.833ZMeta-analysis · Rheumatology (Oxford), 2026.Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idiopathic arthritis: 48 week results from the SELECT-YOUTH open-label studyhttps://currentrheuma.com/studies/long-term-efficacy-safety-upadacitinib-polyarticular-course-juvenile-idiopathic-2026/2026-11-13T09:15:36.833Z2026-11-13T09:15:36.833ZResearch article · Rheumatology (Oxford), 2026.Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung diseasehttps://currentrheuma.com/studies/urinary-2-microglobulin-as-a-prognostic-and-treatment-associated-biomarker-in-2026/2026-11-13T08:15:53.797Z2026-11-13T08:15:53.797ZDiagnostic or prognostic study · Rheumatology (Oxford), 2026.ERN-RITA/PReS recommendations for the diagnosis, classification, monitoring, and treatment of childhood idiopathic (primary) angiitis of the central nervous systemhttps://currentrheuma.com/studies/ern-rita-pres-recommendations-diagnosis-classification-monitoring-treatment-2026/2026-11-13T06:15:29.260Z2026-11-13T06:15:29.260ZGuideline or statement · Ann Rheum Dis, 2026.Validation of rheumatoid arthritis low inflammatory activity: a novel clinical target quantifying inflammatory disease activityhttps://currentrheuma.com/studies/validation-of-rheumatoid-arthritis-low-inflammatory-activity-a-novel-clinical-2026/2026-11-13T06:15:29.260Z2026-11-13T06:15:29.260ZDiagnostic or prognostic study · Ann Rheum Dis, 2026.BMI and Varus Malalignment Compound to Define a High-Risk Phenotype for Compartment-Specific Knee Osteoarthritis Progressionhttps://currentrheuma.com/studies/bmi-and-varus-malalignment-compound-to-define-a-high-risk-phenotype-for-2026/2026-11-13T05:15:37.279Z2026-11-13T05:15:37.279ZCohort study · Osteoarthritis Cartilage, 2026.Screening for Neoehrlichia mikurensis and other emerging tick-borne pathogens in Swedish patients with systemic lupus erythematosus receiving B-cell-targeted therapieshttps://currentrheuma.com/studies/screening-for-neoehrlichia-mikurensis-and-other-emerging-tick-borne-pathogens-in-2026/2026-11-12T17:15:39.386Z2026-11-12T17:15:39.386ZResearch article · Scand J Rheumatol, 2026.Longitudinal trends in vaccination uptake and respiratory infection burden in systemic lupus erythematosus: a population-based cohort studyhttps://currentrheuma.com/studies/longitudinal-trends-in-vaccination-uptake-and-respiratory-infection-burden-in-2026/2026-11-12T12:15:58.454Z2026-11-12T12:15:58.454ZCohort study · Rheumatology (Oxford), 2026.Cluster analysis identifies anti‐synthetase syndrome as a distinct and heterogeneous clinical entity: Analysis from the Classification Criteria for Anti‐Synthetase Syndrome project databasehttps://currentrheuma.com/studies/cluster-analysis-identifies-anti-synthetase-syndrome-as-distinct-heterogeneous-2026/2026-11-12T11:15:54.044Z2026-11-12T11:15:54.044ZResearch article · Arthritis Rheumatol, 2026.Combination targeted therapy with Janus kinase inhibition plus biologic agents in refractory JIA: an international multi-centre case serieshttps://currentrheuma.com/studies/combination-targeted-therapy-with-janus-kinase-inhibition-plus-biologic-agents-2026/2026-11-12T11:15:54.044Z2026-11-12T11:15:54.044ZCohort study · Rheumatology (Oxford), 2026.Creatine and CoQ10 with physical activity on muscle function in children with myositis: a proof-of-concept trialhttps://currentrheuma.com/studies/creatine-and-coq10-with-physical-activity-on-muscle-function-in-children-with-2026/2026-11-12T11:15:54.044Z2026-11-12T11:15:54.044ZRandomized controlled trial · Rheumatology (Oxford), 2026.Endothelial IFI16 drives vasculopathy and profibrotic remodeling in systemic sclerosis by activating JAK/STAT signalinghttps://currentrheuma.com/studies/endothelial-ifi16-drives-vasculopathy-and-profibrotic-remodeling-in-systemic-2026/2026-11-12T11:15:54.044Z2026-11-12T11:15:54.044ZResearch article · Rheumatology (Oxford), 2026.Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.https://currentrheuma.com/studies/oral-glucocorticoids-added-ild-modifying-therapy-systemic-sclerosis-associated-2026/2026-11-12T11:15:54.044Z2026-11-12T11:15:54.044ZCohort study · Arthritis Care Res (Hoboken), 2026.Social and Structural Forces Shaping Reproductive Decision‐Making in Hispanic Women with Systemic Lupus Erythematosus: A Qualitative Studyhttps://currentrheuma.com/studies/social-and-structural-forces-shaping-reproductive-decision-making-in-hispanic-2026/2026-11-12T11:15:54.044Z2026-11-12T11:15:54.044ZResearch article · Arthritis Care Res (Hoboken), 2026.Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trialhttps://currentrheuma.com/studies/durable-additive-disease-control-at-52-weeks-ixekizumab-plus-tirzepatide-2026/2026-11-11T17:15:37.180Z2026-11-11T17:15:37.180ZRandomized controlled trial · Arthritis Rheumatol, 2026.Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Indexhttps://currentrheuma.com/studies/scoping-review-human-longitudinal-studies-biomarkers-associated-risk-developing-2026/2026-11-11T17:15:37.180Z2026-11-11T17:15:37.180ZResearch article · Arthritis Care Res (Hoboken), 2026.Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: clinical associations and methodological heterogeneity—a scoping reviewhttps://currentrheuma.com/studies/anti-phosphatidylserine-prothrombin-antibodies-antiphospholipid-syndrome-2026/2026-11-11T05:17:20.747Z2026-11-11T05:17:20.747ZResearch article · Semin Arthritis Rheum, 2026.Eltrombopag in the treatment of immune thrombocytopenia secondary to SLE: A double-edged swordhttps://currentrheuma.com/studies/eltrombopag-in-the-treatment-of-immune-thrombocytopenia-secondary-to-sle-a-2026/2026-11-10T23:15:28.186Z2026-11-10T23:15:28.186ZCohort study · Lupus, 2026.An association study suggests that PTPN22 and TNFAIP3, but not STAT4, are risk factors for IgG4-related diseasehttps://currentrheuma.com/studies/an-association-study-suggests-that-ptpn22-and-tnfaip3-but-not-stat4-are-risk-2026/2026-11-10T18:15:33.627Z2026-11-10T18:15:33.627ZResearch article · Clin Exp Rheumatol, 2026.IgG4-related Castleman disease: clinical-pathological features and therapeutic implicationshttps://currentrheuma.com/studies/igg4-related-castleman-disease-clinical-pathological-features-and-therapeutic-2026/2026-11-10T18:15:33.627Z2026-11-10T18:15:33.627ZCohort study · Clin Exp Rheumatol, 2026.Pneumocystis jirovecii pneumonia prophylaxis in rare systemic autoimmune rheumatic diseases: a systematic review of randomised controlled trials within the European Reference Network on Connective Tissue and Musculoskeletal Diseaseshttps://currentrheuma.com/studies/pneumocystis-jirovecii-pneumonia-prophylaxis-rare-systemic-autoimmune-rheumatic-2026/2026-11-10T18:15:33.627Z2026-11-10T18:15:33.627ZMeta-analysis · Clin Exp Rheumatol, 2026.The IgG4ward! Foundation guidelines on the treatment of IgG4-related diseasehttps://currentrheuma.com/studies/the-igg4ward-foundation-guidelines-on-the-treatment-of-igg4-related-disease-2026/2026-11-10T05:16:41.340Z2026-11-10T05:16:41.340ZGuideline or statement · Lancet Rheumatol, 2026.CD163+ macrophage infiltration reflects disease activity and early treatment response in lupus nephritishttps://currentrheuma.com/studies/cd163-macrophage-infiltration-reflects-disease-activity-and-early-treatment-2025/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZCohort study · Clin Exp Rheumatol, 2025.The clinical potential of serum autotaxin levels at diagnosis as a biomarker for current activity and subsequent complications in patients with microscopic polyangiitis and granulomatosis with polyangiitishttps://currentrheuma.com/studies/clinical-potential-serum-autotaxin-levels-at-diagnosis-as-biomarker-current-2026/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZCohort study · Clin Exp Rheumatol, 2026.Elevated lactate dehydrogenase and co-infection: predictors of rapidly progressive interstitial lung disease and fatal outcomes in anti-MDA5-positive dermatomyositishttps://currentrheuma.com/studies/elevated-lactate-dehydrogenase-co-infection-predictors-rapidly-progressive-2025/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZCohort study · Clin Exp Rheumatol, 2025.Glycolipid metabolic changes during remission induction in ANCA-associated vasculitis: a retrospective study of the lipid paradoxhttps://currentrheuma.com/studies/glycolipid-metabolic-changes-during-remission-induction-in-anca-associated-2026/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZCohort study · Clin Exp Rheumatol, 2026.Nailfold capillaroscopy by dermatoscope in systemic sclerosis: a systematic review and meta-analysishttps://currentrheuma.com/studies/nailfold-capillaroscopy-by-dermatoscope-in-systemic-sclerosis-a-systematic-2026/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZMeta-analysis · Clin Exp Rheumatol, 2026.Obesity-exacerbated lupus via leptin-induced putrescine depletion and Tfh cell hyperactivationhttps://currentrheuma.com/studies/obesity-exacerbated-lupus-via-leptin-induced-putrescine-depletion-and-tfh-cell-2026/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZResearch article · Clin Exp Rheumatol, 2026.Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesityhttps://currentrheuma.com/studies/retatrutide-once-weekly-in-adults-with-knee-osteoarthritis-pain-and-obesity-2026/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZResearch article · N Engl J Med, 2026.Serum cytokine profiling identifies distinct immune phenotypes in eosinophilic granulomatosis with polyangiitis: interleukin-25- and interleukin-5-driven eosinophilic subtypeshttps://currentrheuma.com/studies/serum-cytokine-profiling-identifies-distinct-immune-phenotypes-eosinophilic-2025/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZCohort study · Clin Exp Rheumatol, 2025.WTAP regulates PTEN through m6A methylation to modulate the inflammatory response in CD4+ T cells from patients with ankylosing spondylitishttps://currentrheuma.com/studies/wtap-regulates-pten-through-m6a-methylation-to-modulate-the-inflammatory-2026/2026-11-09T17:15:24.911Z2026-11-09T17:15:24.911ZCase-control study · Clin Exp Rheumatol, 2026.Perceptions of Rheumatologists on Barriers and Enablers to Adoption of Interdisciplinary Models of Care in Rheumatology in Ontario, Canadahttps://currentrheuma.com/studies/perceptions-of-rheumatologists-on-barriers-and-enablers-to-adoption-of-2026/2026-11-09T16:15:46.851Z2026-11-09T16:15:46.851ZResearch article · Arthritis Care Res (Hoboken), 2026.Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialhttps://currentrheuma.com/studies/efficacy-and-safety-of-obinutuzumab-in-patients-with-active-systemic-lupus-2026/2026-11-09T09:15:57.425Z2026-11-09T09:15:57.425ZRandomized controlled trial · Lancet Rheumatol, 2026.Prevalence and clinical associations of age-related clonal hematopoiesis in systemic sclerosishttps://currentrheuma.com/studies/prevalence-and-clinical-associations-of-age-related-clonal-hematopoiesis-in-2026/2026-11-08T16:16:11.186Z2026-11-08T16:16:11.186ZCase-control study · Rheumatology (Oxford), 2026.Biomarker trajectories and risk of relapse in giant cell arteritis: a multicenter studyhttps://currentrheuma.com/studies/biomarker-trajectories-and-risk-of-relapse-in-giant-cell-arteritis-a-multicenter-2026/2026-11-08T06:15:45.107Z2026-11-08T06:15:45.107ZCohort study · Semin Arthritis Rheum, 2026.Predicting Inactive Disease in Juvenile Idiopathic Arthritis: A Dynamic Machine Learning Approachhttps://currentrheuma.com/studies/predicting-inactive-disease-in-juvenile-idiopathic-arthritis-a-dynamic-machine-2026/2026-11-07T05:15:27.138Z2026-11-07T05:15:27.138ZDiagnostic or prognostic study · Arthritis Rheumatol, 2026.Synovial Tissue‐Guided Interleukin‐17A Inhibition for Refractory Arthritis in a Patient With Systemic Juvenile Idiopathic Arthritishttps://currentrheuma.com/studies/synovial-tissue-guided-interleukin-17a-inhibition-for-refractory-arthritis-in-a-2026/2026-11-07T05:15:27.138Z2026-11-07T17:37:35.947ZResearch article · Arthritis Rheumatol, 2026.Sedative-hypnotic use and its association with osteoporosis and fractures: a national analysis, 1999–2020https://currentrheuma.com/studies/sedative-hypnotic-use-and-its-association-with-osteoporosis-and-fractures-a-2026/2026-11-07T00:15:31.319Z2026-11-07T00:15:31.319ZCross-sectional study · Osteoporos Int, 2026.Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC studyhttps://currentrheuma.com/studies/litifilimab-reduces-skin-and-joint-disease-in-participants-with-sle-additional-2026/2026-11-06T09:16:48.334Z2026-11-06T09:16:48.334ZSecondary analysis · Lupus Sci Med, 2026.Maternal and neonatal outcomes in SLE: comparison of 430 pregnancies from the French GR2 study with 1720 pregnancies from French perinatal surveyshttps://currentrheuma.com/studies/maternal-and-neonatal-outcomes-in-sle-comparison-of-430-pregnancies-from-the-2026/2026-11-06T09:16:48.334Z2026-11-06T09:16:48.334ZCohort study · Lupus Sci Med, 2026.